Helmut Paul

Group Lead Method Development/Validation / Institute Krems Bioanalytics

  • Helmut Paul, MSc | Group Lead Method Development/Validation / Institute Krems Bioanalytics - IMC Fachhochschule Krems

    Helmut Paul, MSc

    Group Lead Method Development/Validation / Institute Krems Bioanalytics
    Institute Krems Bioanalytics

    +43 2732 802 288
    IMC TFZIMC TFZ Objekt 3
  • Immunology, Immunotoxicology, Hematology
  • Project Management
  • Method development, qualification and validation for the analysis and characterization of therapeutic proteins

  • Paul, H., Berg, V., Gangadharan, B.M., Bowen, J., LeBeau, P., Blatny, J., Male, C., Radulescu, V., Diaz, R., Mancuso, M.E., Brown, D.L., Reipert, B.M. (2022): Prospective hemophilia inhibitor PUP study reveals distinct antibody signatures during FVIII inhibitor eradication. Blood Advances, Epub ahead of print.

     Doi: https://doi.org/10.1182/bloodadvances.2022007267

  • Schweiger, H., Rejtö, J., Hofbauer, C.J., Berg, V., Allacher, P., Zwiauer, K., Feistritzer, C., Schuster, G., Ay, C., Reipert, B.M., Pabinger, I. (2022): Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors. Blood Advances, 6(3): 946-958.

     Doi: https://doi.org/10.1182/bloodadvances.2021005745

  • Reipert, B.M., Gangadharan, B., Hofbauer, C.J., Berg, V., Schweiger, H., Bowen, J., Blatny, J., Fijnvandraat, K., Mullins, E.S., Klintman, J., Male, C., McGuinn, C., Meeks, S.L., Radulescu, V.C., Ragni, M.V., Recht, M., Shapiro, A.D., Staber, J.M., Yaish, H.M., Santagostino, E., Brown, D.L. (2020): The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development. Blood Advances, 4(22): 5785–5796.

     Doi: https://doi.org/10.1182/bloodadvances.2020002731

  • Jacobi, N., Seeboeck, R., Hofmann, E., Schweiger, H., Smolinska, V., Mohr, T., Boyer, A., Sommergruber, W., Lechner, P., Pichler-Huebschmann, C., Önder, K., Hundsberger, H., Wiesner, C., & Eger, A. (2017): Organotypic three-dimensional cancer cell cultures mirror drug responses in vivo: lessons learned from the inhibition of EGFR signaling. Oncotarget, 8(64): 107423–107440.

     Doi: https://doi.org/10.18632/oncotarget.22475
Back to overview of staff members